Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
暂无分享,去创建一个
M. Bittrich | M. Krebs | Antonio Giovanni Solimando | G. Fritz | E. Shahini | Endrit Shahini | F. Albanese | Antonio G. Solimando | Max Bittrich | Federica Albanese | Georg Fritz
[1] J. Casanova,et al. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. , 2023, Annual review of immunology.
[2] Á. Kinyó,et al. Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies , 2023, International journal of molecular sciences.
[3] A. Tan,et al. COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients , 2023, Vaccine: X.
[4] P. Tabares,et al. STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure , 2023, Clinical and Experimental Medicine.
[5] H. Wildiers,et al. Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) , 2023, Autoimmunity Reviews.
[6] N. Brunetti,et al. Electrocardiographic Pathological Findings Caused by the SARS-CoV-2 Virus Infection: Evidence from a Retrospective Multicenter International Cohort Longitudinal Pilot Study of 548 Subjects , 2023, Journal of cardiovascular development and disease.
[7] Antonio Giovanni Solimando,et al. Can vitamin D status influence seroconversion to SARS-COV2 vaccines? , 2022, Frontiers in Immunology.
[8] M. Bonifazi,et al. Early administration of tofacitinib in COVID‐19 pneumonitis: An open randomised controlled trial , 2022, European journal of clinical investigation.
[9] D. Ribatti,et al. SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows , 2022, Biomedicines.
[10] C. Foti,et al. SARS-CoV-2 and Skin: New Insights and Perspectives , 2022, Biomolecules.
[11] M. Martinez-Urbistondo,et al. Systemic Autoimmune Diseases in Patients Hospitalized with COVID-19 in Spain: A Nation-Wide Registry Study , 2022, Viruses.
[12] B. LaFleur,et al. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis , 2022, European Journal of Cancer.
[13] Zhuo Li,et al. Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis , 2022, European Journal of Cancer.
[14] A. Sette,et al. Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.
[15] F. Nikbakht,et al. COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety , 2022, Frontiers in Endocrinology.
[16] G. Giardino,et al. The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet) , 2022, Journal of Clinical Immunology.
[17] M. Mulligan,et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease , 2022, The Lancet Rheumatology.
[18] A. Allegra,et al. Involvement of Il-33 in the Pathogenesis and Prognosis of Major Respiratory Viral Infections: Future Perspectives for Personalized Therapy , 2022, Biomedicines.
[19] O. Resta,et al. Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection , 2022, Pathogens and global health.
[20] P. Moss. The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.
[21] M. Diamond,et al. Innate immunity: the first line of defense against SARS-CoV-2 , 2022, Nature Immunology.
[22] A. Bilici,et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study , 2022, Future oncology.
[23] S. Tangye,et al. Severe COVID‐19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals , 2022, Clinical & translational immunology.
[24] Bryan D. Bryson,et al. JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. , 2022, Med.
[25] P. Leone,et al. Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis , 2022, Frontiers in Immunology.
[26] E. Callaway. Beyond Omicron: what’s next for COVID’s viral evolution , 2021, Nature.
[27] Weihao Shao,et al. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis , 2021, International Journal of Infectious Diseases.
[28] J. Underwood,et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency , 2021, Journal of Allergy and Clinical Immunology.
[29] H. Gendelman,et al. Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions , 2021, Frontiers in Immunology.
[30] David W. McDonald,et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[31] M. Dimopoulos,et al. Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine , 2021, British journal of haematology.
[32] A. Sette,et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.
[33] S. Steinberg,et al. Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors , 2021, JTO Clinical and Research Reports.
[34] F. Baldanti,et al. Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study , 2021, Clinical Microbiology and Infection.
[35] F. Baldanti,et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study , 2021, ESMO Open.
[36] B. Baradaran,et al. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery , 2021, Genes.
[37] A. Paradiso,et al. Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection , 2021, Journal of clinical medicine.
[38] E. Holmes,et al. After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.
[39] F. Rovida,et al. Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study , 2021, International Journal of Infectious Diseases.
[40] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[41] G. De Pergola,et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme , 2021, Journal of clinical medicine.
[42] J. Izopet,et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.
[43] L. Cerbone,et al. Serological response to COVID-19 vaccination in patients with cancer older than 80 years , 2021, Journal of Geriatric Oncology.
[44] G. Curigliano,et al. COVID-19 vaccines in patients with cancer , 2021, The Lancet Oncology.
[45] Bjoern Peters,et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 , 2021, Cell Host & Microbe.
[46] A. Sisó-Almirall,et al. SARS-CoV-2 infection in patients with systemic autoimmune diseases. , 2021, Clinical and experimental rheumatology.
[47] G. Giardino,et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity , 2021, The Journal of Allergy and Clinical Immunology: In Practice.
[48] R. Bruno,et al. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay , 2021, Clinical Microbiology and Infection.
[49] F. Giardina,et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice , 2021, Nature.
[50] Jia Xin Yee,et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset , 2021, Med.
[51] J. Schultze,et al. COVID-19 and the human innate immune system , 2021, Cell.
[52] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[53] A. Iafrate,et al. COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.
[54] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[55] Adam C. Labonte,et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway , 2020, Scientific Reports.
[56] V. Procacci,et al. Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department , 2021, Frontiers in Medicine.
[57] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[58] Smita Y. Patel,et al. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience , 2020, Journal of Allergy and Clinical Immunology.
[59] C. Peano,et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, Nature Immunology.
[60] A. Iwasaki,et al. Interferon deficiency can lead to severe COVID , 2020, Nature.
[61] G. Curigliano,et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 , 2020, Annals of Oncology.
[62] B. Lambrecht,et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.
[63] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[64] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[65] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[66] J. Tregoning,et al. Vaccines for COVID‐19 , 2020, Clinical and experimental immunology.
[67] M. Netea,et al. Trained Innate Immunity, Epigenetics, and Covid-19. , 2020, The New England journal of medicine.
[68] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[69] Arthur S Slutsky,et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.
[70] Bernd Bodenmiller,et al. A distinct innate immune signature marks progression from mild to severe COVID-19 , 2020, bioRxiv.
[71] Aaron M. Rosenfeld,et al. Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.
[72] M. Gianfrancesco,et al. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. , 2020, Current opinion in rheumatology.
[73] M. Peluso,et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. , 2020, The Journal of infectious diseases.
[74] Shaoying Huang,et al. The cytokine storm and COVID‐19 , 2020, Journal of medical virology.
[75] S. Fonseca,et al. Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse , 2020, Frontiers in Immunology.
[76] Jian-Piao Cai,et al. Attenuated Interferon and Proinflammatory Response in SARS-CoV-2–Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation , 2020, The Journal of infectious diseases.
[77] V. Torri,et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.
[78] J. Blay,et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR , 2020, European Journal of Cancer.
[79] L. Staudt,et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 , 2020, Science Immunology.
[80] Kemesha S Gabbidon,et al. The Impact of COVID-19 on HIV Treatment and Research: A Call to Action , 2020, International journal of environmental research and public health.
[81] Jun Yu Li,et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[82] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[83] R. López-Vélez,et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.
[84] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[85] P. Calder. Nutrition, immunity and COVID-19 , 2020, BMJ Nutrition, Prevention & Health.
[86] F. Valent,et al. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy , 2020, Joint Bone Spine.
[87] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[88] Meilin Liu,et al. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis , 2020, Journal of Infection.
[89] M. Kamboj,et al. COVID-19 in Children With Cancer in New York City. , 2020, JAMA oncology.
[90] A. Vincent-Salomon,et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area , 2020, Breast Cancer Research.
[91] L. Trupin,et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.
[92] L. Barreiro,et al. Herd Immunity: Understanding COVID-19 , 2020, Immunity.
[93] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[94] A. Paradiso,et al. MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance , 2020, International journal of molecular sciences.
[95] A. Vacca,et al. Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside , 2020, International journal of molecular sciences.
[96] V. Lougaris,et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.
[97] H. Miyashita,et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.
[98] M. Chiarini,et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[99] C. Wang,et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.
[100] S. Gangemi,et al. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases , 2019, International journal of molecular sciences.
[101] G. Mufti,et al. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag , 2019, Haematologica.
[102] F. Dammacco,et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. , 2017, Clinical immunology.
[103] F. Goodrum,et al. Known unknowns: how might the persistent herpesvirome shape immunity and aging? , 2017, Current opinion in immunology.
[104] C. Weyand,et al. Aging of the Immune System. Mechanisms and Therapeutic Targets. , 2016, Annals of the American Thoracic Society.
[105] S. I. Alam,et al. Secretome, surfome and immunome: emerging approaches for the discovery of new vaccine candidates against bacterial infections , 2016, World journal of microbiology & biotechnology.
[106] Brandon J Thomas,et al. Age-Related Gene Expression Differences in Monocytes from Human Neonates, Young Adults, and Older Adults , 2015, PloS one.
[107] Ruslan Medzhitov,et al. Homeostasis, Inflammation, and Disease Susceptibility , 2015, Cell.
[108] L. Notarangelo. Primary immunodeficiencies (PIDs) presenting with cytopenias. , 2009, Hematology. American Society of Hematology. Education Program.